InjectionClinical Overview
Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered strictly by a qualified healthcare professional by slow intravenous infusion diluted in at least 100-200 mL of compatible fluid over a minimum of 60 minutes (or rate not exceeding 10 mg/min) to prevent infusion-related reactions. Therapeutic drug monitoring (trough levels) is standard practice.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Infusion site pain, mild nausea. Rare/Severe: "Red Man Syndrome" (histamine-mediated flushing, erythematous rash on face/neck/torso, and hypotension caused by rapid IV infusion), nephrotoxicity (acute kidney injury), ototoxicity (hearing loss), neutropenia, and DRESS syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box caution for nephrotoxicity and ototoxicity, especially when combined with aminoglycosides, loop diuretics, or piperacillin-tazobactam. Mandatory slow IV infusion rate (minimum 60 minutes) to avoid Red Man Syndrome. Monitor serum trough levels and kidney function routinely.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Vancomycin Hydrochloride for Intravenous Infusion 1000 mg
Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.
Vancomycin Hydrochloride Capsules 250mg
Vancomycin Hydrochloride is a tricyclic glycopeptide bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding with high affinity to the D-alanyl-D-alanine terminus of cell wall peptidoglycan precursors. Indicated intravenously for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA), enterococcal infections, endocarditis, and surgical prophylaxis in high-risk patients. When given orally (capsules), it is not absorbed systemically and acts locally to treat Clostridioides difficile-associated diarrhea (pseudomembranous colitis) and staphylococcal enterocolitis.